Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Jan 2012

Puig-Saus Cristina, Gros Alena, Alemany Ramon, Cascalló Manel

Abstract excerpt

Tumor-associated stromal cells constitute a major hurdle in the antitumor efficacy with oncolytic adenoviruses. To overcome this biological barrier, an in vitro bioselection of a mutagenized AdwtRGD stock in human cancer-associated fibroblasts (CAFs) was performed. Several rounds of harvest at early cytopathic effect (CPE) followed by plaque isolation led us to identify one mutant with large plaque phenotype,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Cytopathogenic Effect, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Stromal Cells

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 21863000
DOI: 10.1038/mt.2011.159
PMCID: PMC3255593

Genes

CPE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.PMID 21863000Read ↗

Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.Semantic proximity Read ↗

Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.Semantic proximity Read ↗

Developing Novel Oncolytic Adenoviruses through BioselectionSemantic proximity Read ↗

Protease-Deleted Adenovirus Vectors and Complementing Cell Lines: Potential Applications of Single-Round Replication Mutants for Vaccination and Gene TherapySemantic proximity Read ↗

FAP-retargeted Ad5 enables <i>in vivo</i> gene delivery to stromal cells in the tumor microenvironmentSemantic proximity Read ↗

Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.Semantic proximity Read ↗

Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sortingSemantic proximity Read ↗

Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachmentSemantic proximity Read ↗

CDC20 is a potential target gene to inhibit the tumorigenesis of MDCK cellsSemantic proximity Read ↗

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.Semantic proximity Read ↗

Accumulation of infectious mutants in stocks during the propagation of fiber-modified recombinant adenoviruses.Semantic proximity Read ↗

Virus-Associated RNA I–Deleted Adenovirus, a Potential Oncolytic Agent Targeting EBV-Associated TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.